Evidence map›Paper›PMID 26299617›Full record

ArticleOncotarget2015

Whole-transcriptome analysis of flow-sorted cervical cancer samples reveals that B cell expressed TCL1A is correlated with improved survival.

Simone Punt, Willem E Corver, Sander A J van der Zeeuw, Szymon M Kielbasa, Elisabeth M Osse, Henk P J Buermans, Cornelis D de Kroon, Ekaterina S Jordanova, Arko Gorter

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Simone PuntDepartment of Pathology, Leiden University Medical Center, Albinusdreef, Leiden, The Netherlands.
Willem E CorverDepartment of Pathology, Leiden University Medical Center, Albinusdreef, Leiden, The Netherlands.
Sander A J van der ZeeuwDepartment of Sequencing Analysis Support Core, Leiden University Medical Center, Albinusdreef, Leiden, The Netherlands.
Szymon M KielbasaDepartment of Bioinformatics Center of Expertise, Leiden University Medical Center, Albinusdreef, Leiden, The Netherlands.
Elisabeth M OsseDepartment of Pathology, Leiden University Medical Center, Albinusdreef, Leiden, The Netherlands.
Henk P J BuermansDepartment of Leiden Genome Technology Center, Leiden University Medical Center, Albinusdreef, Leiden, The Netherlands.
Cornelis D de KroonDepartment of Gynaecology, Leiden University Medical Center, Albinusdreef, Leiden, The Netherlands.
Ekaterina S JordanovaDepartment of Pathology, Leiden University Medical Center, Albinusdreef, Leiden, The Netherlands.
Arko GorterDepartment of Pathology, Leiden University Medical Center, Albinusdreef, Leiden, The Netherlands.
Leiden University Medical Center · NLAmsterdam UMC Location VUmc · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cervical cancer is typically well infiltrated by immune cells. Because of the intricate relationship between cancer cells and immune cells, we aimed to identify both cancer cell and immune cell expressed biomarkers. Using a novel approach, we isolated RNA from flow-sorted viable EpCAM+ tumor epithelial cells and CD45+ tumor-infiltrating immune cells obtained from squamous cell cervical cancer samples (n = 24). Total RNA was sequenced and differential gene expression analysis of the CD45+ immune cell fractions identified TCL1A as a novel marker for predicting improved survival (p = 0.007). This finding was validated using qRT-PCR (p = 0.005) and partially validated using immunohistochemistry (p = 0.083). Importantly, TCL1A was found to be expressed in a subpopulation of B cells (CD3-/CD19+/CD10+/CD34-) using multicolor immunofluorescence. A high TCL1A/CD20 (B cell) ratio, determined in total tumor samples from a separate patient cohort using qRT-PCR (n = 52), was also correlated with improved survival (p = 0.027). This is the first study demonstrating the prognostic value of separating tumor epithelial cells from tumor-infiltrating immune cells and determining their RNA expression profile for identifying putative cancer biomarkers. Our results suggest that intratumoral TCL1A+ B cells are important for controlling cervical cancer development.

Indexed as

AdultAgedAged, 80 and overB-LymphocytesFemaleGene Expression ProfilingHumansMiddle AgedPrognosisProto-Oncogene ProteinsSurvival AnalysisTumor MicroenvironmentUterine Cervical NeoplasmsProto-Oncogene ProteinsTCL1A protein, humanB lymphocytesimmune responseTCL1Atumor microenvironmentuterine cervical cancer

Identifiers

PMID26299617
PMCPMC4770729
OpenAlexW1727252716

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.